A Phase 3 interventional study of Ataluren in Duchenne Muscular Dystrophy, sponsored by PTC Therapeutics. Terminated at 34 sites in 2 countries. Open to male participants. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by PTC Therapeutics · Phase 3, Interventional, and Treatment
Sponsor decision
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing ataluren in Muscular Dystrophy, Duchenne — none open to participants now, none under way, none of them phase 3. ataluren · Muscular Dystrophy, Duchenne.
Among the 14 studies testing ataluren in Muscular Dystrophy, Duchenne, this one is the 2nd largest by enrollment, is one of 2 that started in 2010, is one of 5 in phase 3, and was the 6th registered.
482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →None of the 14 studies testing ataluren in Muscular Dystrophy, Duchenne is open now. The open studies under Muscular Dystrophy, Duchenne, anywhere →
ataluren: first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.
This study: male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2010.
This study's enrollment of 265 is above the median of 25 across 333 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 66 across the 14 interventional studies. Of the 14 that completed or were terminated, 13 (93%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 14 have an industry lead sponsor. The 1 most frequent:
PTC Therapeutics is the lead sponsor of 65 studies on the registry; 3 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 14 (78%) have results posted.
19 studies in Muscular Dystrophy, Duchenne by PTC Therapeutics: none open now, none under way, none of them phase 3. Of 17 finished, 13 (76%) have results posted.
Among the 19 studies in Muscular Dystrophy, Duchenne by PTC Therapeutics, this one is the 2nd largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2010, is one of 6 in phase 3, and was the 6th registered.
PTC Therapeutics’s Muscular Dystrophy, Duchenne studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing ataluren in Muscular Dystrophy, Duchenne, from their registry updates:
Among PTC Therapeutics’s 19 in Muscular Dystrophy, Duchenne:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to assess the safety and tolerability of 10, 10, 20 milligrams per kilogram (mg/kg) ataluren in participants with nmDBMD who had prior exposure to ataluren in a PTC sponsored clinical trial or treatment plan, and siblings of those participants (provided those participants have completed the placebo-controlled portion of the trial).
The treatment will continue under this protocol until consent withdrawal by participants, withdrawal due to worsen condition after initiating ataluren treatment, withdrawal by investigator, withdrawal due to participant unable to tolerate ataluren, participant is eligible to participate in another ataluren nmDBMD clinical trial program initiated by sponsor, study is discontinued by the relevant regulatory authority and/or sponsor, or until ataluren becomes commercially available.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 3 doses of ataluren oral suspension per day (10 mg/kg in the morning, 10 mg/kg at mid-day and 20 mg/kg in the evening).
Drug: Ataluren
Ataluren will be administered as per the dose and schedule specified in the arm.
Also known as: PTC124, Translarna
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A TEAE was defined as an AE that occurred or worsened on or after the first dose of ataluren and up to 4 weeks after the last dose of ataluren. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'.
Time frame: Baseline up to end of study (up to approximately 15 years)
| Milestone | Ataluren |
|---|---|
| Started | 265 |
| Received at least 1 dose of study drug | 265 |
| Completed | 0 |
| Not completed | 265 |
| Withdrew: Adverse event | 29 |
| Withdrew: Lost to follow-up | 16 |
| Withdrew: Withdrawal by subject | 67 |
| Withdrew: Investigator decision | 5 |
| Withdrew: Protocol violation | 5 |
| Withdrew: Study termination | 111 |
| Withdrew: Other than specified | 32 |
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A TEAE was defined as an AE that occurred or worsened on or after the first dose of ataluren and up to 4 weeks after the last dose of ataluren. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'.
| Participants | Ataluren |
|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 242 |
Collected over Baseline up to end of study (up to approximately 15 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ataluren | 14/265 (5.3%) | 90/265 (34%) | 241/265 (90.9%) |
| Event | Ataluren |
|---|---|
| Femur fractureInjury, poisoning and procedural complications | 26/265 |
| PneumoniaInfections and infestations | 18/265 |
| InfluenzaInfections and infestations | 6/265 |
| DehydrationMetabolism and nutrition disorders | 5/265 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 5/265 |
| Cardiac failureCardiac disorders | 4/265 |
| SepsisInfections and infestations | 4/265 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 4/265 |
| Cardiac arrestCardiac disorders | 3/265 |
| Compression fractureInjury, poisoning and procedural complications | 3/265 |
| Event | Ataluren |
|---|---|
| NasopharyngitisInfections and infestations | 94/265 |
| Disease progressionGeneral disorders | 59/265 |
| COVID-19Infections and infestations | 54/265 |
| VomitingGastrointestinal disorders | 51/265 |
| FallInjury, poisoning and procedural complications | 47/265 |
| CoughRespiratory, thoracic and mediastinal disorders | 46/265 |
| DiarrhoeaGastrointestinal disorders | 45/265 |
| HeadacheNervous system disorders | 43/265 |
| PyrexiaGeneral disorders | 42/265 |
| InfluenzaInfections and infestations | 42/265 |
The As-treated population included all participants who received at least 1 dose of ataluren.
| Age, Continuous(years) | Ataluren |
|---|---|
| Mean | 10.9 ± 3.99 |
| Sex: Female, Male(Participants) | Ataluren |
|---|---|
| Female | 0 |
| Male | 265 |
| Ethnicity (NIH/OMB)(Participants) | Ataluren |
|---|---|
| Hispanic or Latino | 20 |
| Not Hispanic or Latino | 119 |
| Unknown or Not Reported | 126 |
| Race/Ethnicity, Customized(Participants) | Ataluren |
|---|---|
| Race — Asian | 20 |
| Race — Black or African American | 8 |
| Race — White | 205 |
| Race — Other | 22 |
| Race — Missing | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2010 to primary completion in Feb 2026, 182 months.
Results were first posted in Oct 2026, 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
Sponsor decision
Sponsor decision
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ataluren
Muscular Dystrophy, Duchenne →